1stOncology™: Cancer Intelligence Service – Page 12503 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Novigenix-Led Consortium Secures Eurostars Funding to Develop Multi-Omics Test for Colon Cancer Detection and Monitoring

On January 21, 2020 Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, reported that a consortium, including Maastricht University (The Netherlands), Biolizard and the KU Leuven (Belgium), in addition to Novigenix, has been awarded a grant up to €1 million to develop a blood based multi-omics colorectal cancer (CRC) test (Press release, Novigenix, JAN 21, 2020, View Source [SID1234553375]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The aim of the consortium is to develop a blood based test based on transcriptomic and epigenetic biomarkers for early detection and relapse monitoring in CRC patients. The biomarker development strategy will leverage transcriptome profiling of whole blood and candidate tumor DNA methylation markers in cell free-DNA. Moreover, the consortium will develop an automated and structured data analysis process, including the most advanced machine learning methods, and validate multi-omics signatures.

The members of consortium balanced between industrial and academic partners. Novigenix’s will leverage its core competencies of the Immuno-Transcriptomics technology and Biolizard will focus on biological data integration, bioinformatics analysis, pipeline implementation and will provide artificial intelligence solutions. The group of Prof. dr. Manon van Engeland at Maastricht University brings unique expertise on CRC DNA methylation, whereas the Molecular Digestive Oncology group of Prof. dr. Sabine Tejpar at KU Leuven adds a clinical network for prospective collection of biological specimens and data interpretation.

"This Eurostars project combines excellent, world-leading science and technologies in a consortium dedicated to making significant advances in how colorectal cancer is detected and its treatment monitored," said Dr. Jan Groen, CEO of Novigenix. "We believe the outcome of this project, a potential omics-based test, will be important for the diagnosis and disease management of CRC patients."

About Eurostars

Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world. Eurostars is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020. For more information visit View Source

Advaxis, Inc. Announces Pricing Of $10.5 Million Registered Direct Offering

On January 21, 2020 Advaxis, Inc. (Nasdaq: ADXS) (the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, reported it has entered into a definitive agreement with two institutional investors for the purchase and sale of 10,000,000 shares of the Company’s common stock at an offering price of $1.05 per share, for gross proceeds of $10.5 million before deducting fees and other estimated offering expenses, pursuant to a registered direct offering (the "Offering") (Press release, Advaxis, JAN 21, 2020, View Source [SID1234553374]). The Company has also agreed to issue to those investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 5,000,000 shares of the Company’s common stock. The warrants will be exercisable on the six-month anniversary of issuance and will have a five-year term and an exercise price of $1.25 per share.

The Company expects to use the net proceeds from the Offering to fund its continued research and development initiatives in connection with its product pipeline including, but not limited to, in its ADXS-HOT program and potential new studies for its ADXS-PSA drug candidate, and for general corporate purposes. The Offering is expected to close on or about January 23, 2020, subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-226988) previously filed with the U.S. Securities and Exchange Commission (the "SEC"), and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) under the Securities Act, which became effective upon filing on August 30, 2018. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2006 or email: [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. Copies of the Supplement, the Base Shelf Prospectus and the Registration Statement may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected].

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020

On January 21, 2020 Seattle Genetics, Inc. (Nasdaq: SGEN) reported that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets (Press release, Seattle Genetics, JAN 21, 2020, View Source [SID1234553373]). Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, February 6, 2020
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Telephone 800-353-6461 (domestic) or +1 334-323-0501 (international); conference ID 7290215
Webcast with slides available at www.seattlegenetics.com in the Investors section
REPLAY access

Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, February 6, 2020 through 5:00 p.m. PT on Sunday, February 9, 2020 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 7290215
Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section

Propanc Biopharma Receives Advance Overseas Finding from Innovation and Science Australia

On January 21, 2020 Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, reported that a Certificate for Advance Overseas Finding was received from the Board of Innovation and Science Australia to receive up to a 43.5% "cash back" benefit from overseas R&D expenses (Press release, Propanc, JAN 21, 2020, View Source [SID1234553372]). The finding relates to the planned Phase 1 clinical trial – Multiple Ascending Dose Studies of proteolytic proenzymes for the treatment of pancreatic cancer, for 2018/19 and the two following financial years.

Overseas activities to be undertaken include the development of an analytical assay for the quantification of active pharmaceutical ingredients in the Company’s lead product candidate, PRP, and its manufacture of the finished product for the Phase 1 clinical trial. The finding from the Board agreed there is a significant link between the two supporting activities and the planned Phase 1 clinical trial, and the two activities cannot be conducted solely in Australia. The Phase 1 clinical trial is planned to be conducted at the Peter Mac Center, one of the world’s leading cancer research, education and treatment centers, globally and is Australia’s only public hospital solely dedicated to caring for people affected by cancer. To qualify for the advance overseas finding, R&D expenditure incurred overseas will not exceed expenditure on local, Australian R&D activities, which will also receive up to a 43.5% cashback benefit. In other words, overseas versus Australian R&D expenses must not exceed a 50:50 split.

"Both the R&D tax incentive program and the advance overseas finding is an attractive benefit for R&D companies to undertake clinical trials in Australia, as funds allocated towards clinical programs will extend further, by reinvesting the cash benefits received back into research," said James Nathanielsz, Propanc’s Chief Executive Officer. "We’re also in the fortunate position that Australia’s leading cancer treatment center, Peter Mac, is right here in our backyard. As a result of the tax incentive provided by the Australian Government, we look forward to progressing positive discussions with Peter Mac about our Phase 1 clinical trial for PRP in the near future."

Seattle Genetics Achieves Milestone Following European Commission Approval of Roche’s Polivy® (Polatuzumab Vedotin)

On January 21, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy (polatuzumab vedotin). Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ technology (Press release, Seattle Genetics, JAN 21, 2020, View Source [SID1234553371]). It was developed and is commercialized by Roche/Genentech. Polivy was approved in combination with bendamustine plus MabThera (rituximab) (BR) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. Polivy was granted PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of people with R/R DLBCL in 2017.

"In addition to our two marketed ADC products ADCETRIS (brentuximab vedotin) and the recently FDA-approved PADCEV (enfortumab vedotin-ejfv), the European Commission approval of Polivy highlights the increasing importance of ADCs in the treatment of cancer," said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Across our internal and collaborator pipelines, there are more than ten ADCs in clinical development employing our proprietary technology. We continue to lead in the field of ADCs with our novel linker systems, cell-killing payloads and conjugation technologies."

Seattle Genetics’ ADC technology combines the specificity of monoclonal antibodies, innovative linker systems and potent cell-killing agents to treat cancer. The technology has been licensed to several companies, including Roche/Genentech and GlaxoSmithKline. Under the terms of these agreements, each licensee company has rights to use the technology with antibodies against specified targets. The licensee is responsible for research, product development, manufacturing and commercialization. Seattle Genetics is entitled to receive fees, progress-dependent milestone payments and royalties on worldwide net sales of any resulting ADC products.